Mainz Biomed N.V. (“Mainz Biomed”) , a molecular genetics diagnostic company specializing in the early detection of cancer, ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

Lowering barriers to CRC screening is crucial in empowering both patients and healthcare professionals in early cancer detection. One key initiative is increasing accessibility through at-home testing ...

Gabbi’s telehealth solution provides logistics and educational support to assess breast cancer risk. Patients identified as potentially high risk are connected with a Gabbi clinician to be evaluated ...

"We are finding the 3D structure of the genome," said Satoshi Namekawa, professor of microbiology and molecular genetics at ...

Molecular detection technologies help scientists rapidly and reliably find and address ever-evolving pathogens with optimal accuracy and sensitivity.

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that ...

Highlights,Institutional investors adjusted their holdings in Myriad Genetics.,The company reported revenue growth in the latest quarter.,Myriad Genetics specializes in molecular diagnostic ...

and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...